| Title of Invention | IMMUNOSUPPRESSANT COMPOUNDS |
|---|---|
| Abstract | The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction. |
| Full Text | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS CROSS-REFERENCE TO RELATED APPLICATIONS [0001) This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 60/547,757, filed February 24, 2004. The disclosure of the priority application is incorporated herein by reference in its entirety and for all purposes. BACKGROUND OF THE INVENTION Field of the Invention [0002] The invention provides a novel class of immunosuppressant compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction. Background [0003] EDG receptors belong to a family of closely related, lipid activated G- protein coupled receptors. EDG-1, EDG-3, EDG-5, EDG-6, and EDG-8 (also respectively termed SI PI, S1P3, SIP2, SIP4, and S1P5) are identified as receptors specific for sphingosine-1-phosphate (SIP). EDG2, EDG4, and EDG7 (also termed LPA1, LPA2, and LPA3, respectively) are receptors specific for lysophosphatidic (LPA). Among the SIP receptor isotypes, EDG-1, EDG-3 and EDG-5 are widely expressed in various tissues, whereas the expression of EDG-6 is confined largely to lymphoid tissues and platelets, and that of EDG-8 to the centra) nervous system. EDG receptors are responsible for signal transduction and are thought to play an important role in cell processes involving cell development, proliferation, maintenance, migration, differentiation, plasticity and apoptosis. Certain EDG receptors are associated with diseases mediated by lymphocyte interactions, for example, in transplantation rejection, autoimmune diseases, inflammatory diseases, infectious diseases and cancer. An alteration in EDG receptor activity contributes to the pathology and/or symptomology of these diseases. Accordingly, molecules that themselves alter the activity of EDG receptors are useful as therapeutic agents in the treatment of such diseases. [0004] [0005] In which: [0006] n is chosen from 0,1 and 2; m is chosen from 1, 2 and 3; [0007] R1 is chosen from C6-C10aryl and C6-C10 heteroaryl; wherein any aryl or heteroaryl of R1 is optionally substituted by a radical chosen from C6-C10arylCo-4aIkyl, C5. 6heteroarylCo-4alkyl, C3-8cycloa)kylCo-4alkyl, C3-6sheterocycioalkylC0-4alkyl orC1-C10alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R( can be optionally substituted by 1 to 5 radicals chosen from halo, C1-10lkyl, C1-10oalkoxy, halo-substituted-C1- loalkyl and halo-substituted-C1-10aikoxy; and any alkyl group of R1 can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, -S(0)r-, -NR7- and -O- ; wherein R? is chosen from hydrogen and C1-6alkyl; [0008] R2, R3, R4 and R5 are independently chosen from hydrogen, halo, hydroxy, C1-10alkyl, C1-10alkoxy, halo-substituted-C1-C10alkyl and haio-substituted-C1-10alkoxy; [0009] A is chosen from -XiC(o)OR7, -X,OP(o)(OR7)2, -X,P(o)(OR7)2, - X,Po)OR7, -XiS(o)2OR7, -X|P(0)(R7)OR7 and 1h-tetrazol-5-yl; wherein X, is chosen from a bond, C1-3alkylene C2-3alkenyIene and R7 is chosen from hydrogen and Chalky!; [0010] B is CR8R9, wherein R8 and R9 are independently chosen from hydrogen, hydroxy, C1-.10alkyl, C1-10alkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-. 10 alkoxy; [0011 ] E is chosen from CR8or N; wherein Rg is chosen from hydrogen, hydroxy, C1-C10alkyl, C1-10alkoxy, haIo-substituted-C1=10alkyl and halo-substituted-C1-10alkoxy; orB is CR9 and E is carbon and B and E are connected via a double bond; [0012] X is a bond or is chosen from -X1OX2-, -X)NR7X2-, -XiC(o)NR7X2- - XiNR7C(o)Xr-, -XtS(o)X2- -X,S(o)2X2-, -X,SX2- C4.6heteroarylene and - X(ON=C(R?)X2-; wherein X, and X2 are independently chosen from a bond, C1-3alkylene and C:.3alkenylene; R7 is chosen from hydrogen and C|.6alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and Ci^alkyl; [0013] Y is chosen from C1-10aryl and C1-10heteroaryl, wherein any aryl or heteroaryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydoxy, nitro, C1-C10alkyi, C1-C10alkoxy, halo-substituted C1-C10alkyl and halo-substituted C1-C10alkoxy; [0013] and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds. [0014] A second aspect of the invention is a pharmaceutical composition which contains a compound of Formula 1 or an N-oxide derivative, individual isomer or mixture of isomers thereof, or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients. [0015] A third aspect of the invention is a method for treating a disease in an animal in which alteration of EDG receptor mediated signal transduction can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomer or mixture of isomers thereof; or a pharmaceutically acceptable salt thereof. [0016] A fourth aspect of the invention is the use of a compound of Formula 1 in the manufacture of a medicament for treating a disease in an animal in which alteration of EDG receptor mediated signal transduction contributes to the pathology and/or symptomology of the disease. [0017] A fifth aspect of the invention is a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts thereof. DESCRIPTION OF THE PREFERRED EMBODIMENTS [0018] The invention provides compounds that are useful in the treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. Also provided are methods for treating such diseases or disorders. Definitions (0019] In this specification, unless otherwise defined: [0020] "Alkyl" as a group and as a structural element of other groups, for example halo-substituted-alkyl, alkoxy, acyl, alkylthio, alkylsulfonyl and alkylsulfinyl, can be either straight-chained or branched. "Aikenyl" as a group and as a structural element of other groups contains one or more carbon-carbon double bonds, and can be either straight-chain, or branched. Any double bonds can be in the cis- or trans- configuration. A preferred aikenyl group is vinyl. "Alkynyl" as a group and as structural element of other groups and compounds contains at least one C=C triple bond and can also contain one or more C=C double bonds, and can, so far as possible, be either straight-chain or branched. A preferred alkynyl group is propargyl. Any cycloalkyl group, alone or as a structural element of other groups can contain from 3 to 8 carbon atoms, preferably from 3 to 6 carbon atoms. "Aikylene" and "alkenylene" are divalent radicals derived from "alkyl" and "aikenyl" groups, respectively. In this application, any alkyl group of R1 can be optionally interrupted by a member of the group selected from -S-, -S(O)-, -S(o)2~, -NR3- and -O- (wherein R3 is hydrogen or C1-6alkyl). These groups include -CHr-o-CH2-, -CH2-S(o)2-CH2- -(CH2)2~NR3-CH2-, -CH2-o-(CH2)2-> and the like. [0021] "Aryl" means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms. For example, C1-6aryl can be phenyl, biphenyl or naphthyl, preferably phenyl. "Arylene" means a divalent radical derived from an aryl group. For example, arylene as used in this application can be phenylene, biphenylene, naphthylene and the like. [0022] "Halo" or "halogen" means F, CI, Br or I, preferably F or CI. Halo- substituted alkyl groups and compounds can be partially halogenated or perhalogenated, whereby in the case of multiple halogenation, the halogen substituents can be identical or different. A preferred perhalogenated alkyl group is for example trifluoromethyl. [0023J "Heteroaryl" means aryl, as defined in this application, provided that one or more of the ring carbon atoms indicated are replaced by a hetero atom moiety selected from N, 0 or S, and each ring is comprised of 5 to 6 ring atoms, unless otherwise stated. For example, heteroaryl as used in this application includes thiophenyl, pyridinyl, furanyl, isoxazolyl, benzoxazolyl or benzo[l,3]dioxolyl, preferably thiophenyl, furanyl or pyridinyl. "Heteroarylene" means heteroaryl, as defined in this application, provided that the ring assembly comprises a divalent radical. [0024] As used in the present invention, an EDG-l selective compound (agent or modulator) has a specificity that is selective for EDG-l over EDG-3 and over one or more of EDG-5, EDG-6, and EDG-8. As used herein, selectivity for one EDG receptor (a "selective receptor") over another EDG receptor (a "non-selective receptor") means that the compound has a much higher potency in inducing activities mediated by the selective EDG receptor (e.g., EDG-l) than that for the non-selective S1 P-specific EDG receptor. If measured in a GTP-yS binding assay (as described in the Example below), an EDG-l selective compound typically has an EC50 (effective concentration that causes 50% of the maximum response) for a selective receptor (EDG-l) that is at least 5, 10, 25, 50, 100, 500, or 1000 fold lower than its EC50 for a non-selective receptor (e.g., one or more of EDG-3, EDG-5, EDG-6, and EDG-8). Detailed Description of the Invention [0025] The invention provides compounds that are useful for treating or preventing diseases or disorders that are mediated by lymphocyte interactions. In one embodiment, for compounds of Formula I, R1 is chosen from phenyl, naphthyl and thiophenyl optionally substituted by C6.-10arylC0-4alkyl, C5-.6heteroarylCo-4alkyl, C3. 8cycloalkyiCo-4alkyl, C3.gheterocycloaIkylCo^alkyl or C1-C10alkyl; wherein any aryl, heteroaryl, cycloalkyi or heterocycloalkyi group of R1 can be optionally substituted by 1 to 5 radicals chosen from halo, Cnoalkyl, C1-C10alkoxy, halo-substituted-C1-10aIkyI and halo-substituted-C1-10alkoxy; and any alkyl group of Rj can optionally have a methylene replaced by an atom or group chosen from -S~, -S(O)-, -S(o)2-, -NR7- and -O-; wherein R7 is hydrogen or C1-6alkyl. [0026] In another embodiment, A is chosen from -X1C(o)OR7 and 1h-tetrazol-5- yl; wherein X is chosen from a bond, C1-3alkylene and C1-10alkenylene and R7 is chosen from hydrogen and C1-6 alkyl. [0027] In a further embodiment, X is chosen from: [0028] wherein the left and right asterisks of X indicate the point of attachment between R1 and Y of Formula I, respectively; R7 is chosen from hydrogen and Chalky; and w are independently 0,1, 2 or 3. (0029] In another embodiment, Y is chosen from: [0030] wherein R7 is hydrogen or Chalky!; and the left and R1ght asteR1sks of Y indicate the point of attachment between X and E of Formula I, respectively. [0031] In a further embodiment, R1 is chosen from: [0032] wherein the asteR1sk is the point of attachment of R( with X; R10 is C6-. 10 arylC0-4 alkyl, C5-6heteroarylC0_4aIkyI, C3-6cycloalkylC1-4alkyI, C3-6heterocycloalkylCo- 4alkyl or C1-C10alkyl; wherein any aryl, heteroaryl, cycioalkyi or heterocycloalkyl group of R1o can be optionally substituted by 1 to 3 radicals chosen from halo, C1-C10alkyl, C1-10a!koxy, haio-substituted-C1-10alkyI and halo-substituted-C1-C10alkoxy; and any alkyl group of R30 can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, - S(0)r-, -NR7- and -O-; wherein R7 is hydrogen or Cl.-6alkyl; and R11 is selected from halo, C1-C10alkyl, C1-C10alkoxy, halo-substituted«C1-C10alkyl and halo-substituted-Ci_ioaIkoxy. [0033] Preferred are compounds selected from: 3-{4-[6-(4-CyclohexyI-3- tR1f1uoromethyl-benzyloxy)-pyR1din-3-yI]-pipcrazin-I-yI}-propionic acid; 3-{4-[6-(4-CycIohexyl"3-tR1fluoromethyl-phenoxymethyl)-pyR1din-3-yl]-piperazin-l-yl}-propionic acid; 3-{4-[6-(4-Cyclohexyl-3-tR1fluoromethyl-benzyloxy)-pyR1dazin-3-yI]-piperazin^l-yl}-propionic acid; 3-{4-[2-(4-Cyclohexyl-3-tR1fluoromethyl-benzyloxy)-pyR1midin-5-yI]- piperazin-1-yl}-propionic acid; 3-{4-Hydroxy-4-[2-(2-tR1fluoromethyl-biphenyl-4-yI)-benzo[b]thiophen-5-yI]-pipeR1din-l-yl}-propionicacid; 3-{4-[2-(2-TR1fluoromethyI-biphenyi-4-y!)-benzo[b]thiophen-5-yl]-3,6-dihydro*2H-pyR1din-1-yl}-propionic acid; 3-(3-{4-[3-(2-TR1fluoromethyI-biphenyi-4-yl)-[i,2,4]oxadiazol"5-yl]-pheny!}-pyrrolidin-]-y!)-propionic acid; 3-(3-{3-[5-(4-Cyclohexy!-3-tR1fluoromethyl-phenyl)-[l t3,4]oxadiazoI-2-yl]-phenyI}-pyrrolidm-l-yl)-propionicacid; 3-(3-{3-[5-(2-TR1fluoromethyl-biphcnyl-4-yI)-[l,3,4]oxadiazoi-2-yl]-phenyl}-pyrrolidin-l-yt)-propionicacid; 3-(3-{4.[3-(4-Cyclohexyl-3-tR1fluoromethyl-phenyI)-[l,2,4]oxadiazol-5-yl]-phenyI}-pyrrolidin-l-y!)-propionic acid; 3-(4«{4-[5-(4-Cyclohexyl-3*tR1fluoromethyl-phenylHl,3,4]oxadiazol-2-yl]-phenyl}«pipeR1din-l-yl)-propionic acid; 3-(3-{4»[5-(4-Cyc]ohexyI-3-tR1fluoromethyl-phenyl)-[l,3,4]oxadiazoI-2-yl]-phenyl}-pyrrolidin-l-yl)-propionicacid;3-(3-{4-[5-(2-TR1fluoromethyl-biphenyl-4-y])-[l,3,4]oxadiazol-2-yI]"phcnyI}-pyrroIidin-NyI)-propionicacid; 3-(4-{4-[5-(2-TR1fluoromethyl-biphenyM-yO-l^-joxadiazol^-yl--phenyiJ-pipeR1din-l-ylJ-propionic acid;3-(3-{4-[5-(4-Cyclohexyl-3-tR1f1uoromethyi-phenyI)-[1,3,4]oxadiazoU2-yl]-phenyi}-azetidin-1-yl)-propionicacid; 3-(3-{4-f5-(2-TR1fluoromethyl-biphenyl-4-y!)-[l,3,4]oxadiazoI-2-yl]-phenyI}-azetidin-l-yl)-propionicacid; 3-(4-{4-[5-(3-TR1fluoromethyl-phenyI)-[l,3,4]oxadiazoI-2-yI]-phenyI}-pipcR1din-l-yI)-propionicacid; 3-{4-[6-(2-TR1fluoromethyl-biphenyl-4-yIoxymethyI)-pyR1din-3-yl]-piperazin-l-yl}-propionic acid; and 3-{4-[4-(2-TR1fluoromethyl-biphenyI-4-ylsulfanylmethyl)-phenyl]-pipeR1din-l-yl}-propionic acid. [0034] [0035] in which E is selected from N and CH; m and n are independently selected from 0 and 1; v and w are independently selected from 0 and 1; R1o is selected from cyclohexyl, pipeR1dinyl, tetrahydro-thiopyran-4-yl, phenyl, phenoxy and phenylsulfanyl; wherein any cyclohexyl, pipeR1dinyl, tetrahydro-thiopyran-4-yl, phenyl, phenoxy and phenylsulfanyl of R10 can be optionally substituted by 1 to 3 radicals independently selected from methyl and isopropyl; R11 is selected from methyl, trifluoromethyl and ethyl; and R11 is selected from hydrogen, ethyl and methoxy. [0036] Preferred are compounds selected from: 3-{4-[4-(4-Cyclohexyl-3-methyl- phenoxymethyI)-pheny!]-pipeR1din-l-yl}-propionic acid; 3-{4-[4-(4-PipeR1din-]-yI-3-tR1fluoromethyl-phenoxymethyI)-phenyI]-pipeR1din-1-yl}-propionic acid; 3-(4-{4-[3-Methyl-4-(tetrahydro-thiopyran-4-yl)-phenoxymethyl]-phenyl}-pipeR1din-l-yl)-propionic acid; 3-{4-[4-(4-Cyclohexy!-3-tR1fluoromethyl-benzyloxy)-phenyl]-pipeR1din-1 -yl} -propionic acid; 3-{4-[4-(4-Cyclohexyl-3-tR1fluoromethyl-benzyloxy)-2-ethyl-phenyI]-piperazin-l-y(}-propionic acid; 3-{4-[4-(2-Methyl-biphenyl-4-yloxymethyl)-phenyl]-pipeR1din-l-yl}-propionic acid; 3-{4-[4-(2-TR1fluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-pipeR1din-l-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-tR1fluoromethyl-phenoxymethyI)-phenyl]-pipeR1din-1 -yl}-propionic acid; 3-{4-[4-(3'-Methyl-2-tR1fluoromethyl-biphenyl-4-yloxymethy()-phenyl]-pipeR1din-l-yI}-propionicacid; 3-{3-[4-(4-CycIohexyl-3-tR1fluoromethyl-phenoxymethyI)-phenyl]-pyrroIidin-l-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-ethy!-phenoxymethyl)-phenyl]-pipeR1din-l-yl}-propionic acid; 3-{3-[4-(2-TR1fluoromethyl-biphenyi-4-yloxymethyi)-phenyI]-pyrro!idin-l-yl}-propionic acid; 3-(4-{4-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-tR1fluoromethyl-phenoxymethyl]-phenyl}-pipeR1din-l-yl)-propionic acid; 3-{3-[4-(4-Cyclohcxyl-3-tR1fluoromethyl-benzyloxy)-phenyl]-azetidin-l-yl}-propionic acid; 3-{3-[4-(2-TR1fluoromethyl-biphenyi-4-yIoxymethyl)-phenyl]-azetidin-l-yI}-propionicacid; 3-{4-[2-Ethyl-4-(2-tR1fluoromethyI-bipheny-4-yloxymethyl)-phenyI]-pipeR1din-1-yl}-propionic acid; 3-{3-[4-(4-CyclohexyI-3-tR1fluoromethyl-benzyloxy)-phenyl]-pyrrolidin-l-yl}-propionicacid; 3-{4-[4-(4-CycIohexyI-3-tR1fIuoromethyl-benzyIoxy)-2-ethyI-phenyl]-pipeR1din-l-yI}-propionic acid; 3-{4-[4-(4'-Methyl-2-tR1f!uoromethyl-biphenyl-4-yloxymethyl)-pheny!]-pipeR1din-J-yl}-propionic acid; 3-{4-[4-(4-Phenoxy-3-tR1fluoromethyl-phenoxymethyl)-phenyl]-pipeR1din-I-yl}-propionic acid; 3-{4.[4-(4-Cyclohexyl-3-tR1fluoromethyl-phenoxymethyl)-2-methoxy-phenyl]-piperazin-l-yl}-propionic acid; 3-{4-[4-(2-TR1fluoromethyl-btphenyl-4-yImethoxy)-phenyl]-pipeR1din-]-yI}-propionic acid; 3-{3-[4-(2-TR1fluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-pyrroiidin-I-yI}-propionic acid; 3-{3-[4-(2-TR1fluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-azetidin-l-yl}-propionic acid; 3-{4-[4-(4-fsobutyl-3-tR1fluoromethyl-benzyloxy)-phenyl]-pipeR1din-!-yl}-propionic acid; 3-{4-[4-(4-PhenyIsulfanyl-3-tR1fluoromethyI-phenoxymethyl)-phenyl]- pipeR1din-l-yl}-propionic acid; l-(lH-Tetrazol-5-ylmethyl)-4-[4-(2-tR1fluoromethyl-bipheny!-4-ylmethoxy)-phenyl]-pipeR1dine; 1 -[2~(1 H-Tetrazol-5-yl)-ethyI]-4-[4-(2-tR1fluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-pipeR1dine; 3-{4-[4-(2,4'-Dimethyl-bipheny!-4-yloxymethyI)-phenyl]-pipeR1din-l-yI}-propionic acid; 3-{4-[4-(2,4'-Dimcthyl-biphenyl-4-ylmethoxy)-phenyl]-pipeR1din-l-yl}-propionic acid; 3-{4-[4-(2-Ethyi-biphenyl-4-yloxymethyl)-phenyl]-pipeR1din-l-yl}-propionic acid 4-yloxymethyI)-phenyI]-pipeR1din-l -yI}-propionic acid; (2-{4-[4-(2-TR1fluoromethyl-biphenyl-4-yIoxymethyI)-phenyl]-pipeR1din-I-yl}-ethyl)-phosphonic acid; 2-{4-[4-(2-TR1nuoromethyl-biphenyl-4-yloxymethyl)-phenyl]-pipeR1din-l-yl}-ethanesulfonic acid; and PhosphoR1c acid mono-(2-{4-[4~(2-tR1fluoromethyl-biphenyl-4-yIoxymethyl)-phenyl]-pipeR1din-1 -yl} -ethyl) ester. [0037] Further preferred compounds are shown in the examples and table 1, infra. [0038] The invention provides forms of the compound that have the hydroxyl or amine group present in a protected form; these function as prodrugs. Prodrugs are compounds that are converted into an active drug form after administration, through one or more chemical or biochemical transformations. Forms of the compounds of the present invention that are readily converted into the claimed compound under physiological conditions are prodrugs of the claimed compounds and are within the scope of the present invention. Examples of prodrugs include forms where a hydroxyl group is acylated to form a relatively labile ester such as an acetate ester, and forms where an amine group is acylated with the carboxylate group of glycine or an L-amino acid such as seR1ne, forming an amide bond that is particularly susceptible to hydrolysis by common metabolic enzymes. [0039] Compounds of Formula I can exist in free form or in salt form, e.g. addition salts with inorganic or organic acids. Where hydroxy] groups are present, these groups can also be present in salt form, e.g. an ammonium salt or salts with metals such as lithium, sodium, potassium, calcium, zinc or magnesium, or a mixture thereof. Compounds of Formula I and their salts in hydrate or solvate form are also part of the invention. [0040] When the compounds of Formula I have asymmetR1c centers in the molecule, vaR1ous optical isomers are obtained. The present invention also encompasses enantiomers, racemates, diastereoisomers and mixtures thereof. Moreover, when the compounds of Formula I include geometR1c isomers, the present invention embraces c is- compounds, trans-compounds and mixtures thereof. Similar considerations apply in relation to starting mateR1als exhibiting asymmetR1c carbon atoms or unsaturated bonds as mentioned above. Methods and Pharmaceutical Compositions for Treating Immunomodulatory Conditions [0041] The compounds of Formula I in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g. lymphocyte recirculation modulating properties, for example, as indicated by the in vitro and in vivo tests of Example 56 and are therefore indicated for therapy. Compounds of Formula I preferably show an EC50 in the range of 1 x 10"n to I x 10"5 M, preferably less than 50nM. The compounds exhibit selectivity for one or more EDG/S1P receptors, preferably EDG-l/SI P-1. EDG-1/S1P-1 selective modulators of the present invention can be identified by assaying a compound's binding to EDG-1/S1P-1 and one or more of the other EDG/S1P receptors (e.g., EDG-3/S1P-3, EDG-5/S1P-2, EDG-6/S1P-4, and EDG-8/S1P-5). An EDG-l/SlP-1 selective modulator usually has an EC50 for the EDG-1 /SIP-1 receptor in the range of 1 x 10"M to 1 x 10'5 M, preferably less than 50 nM, more preferably less than 5 nM. It also has an EC50 for one or more of the other EDG/S IP receptors that is at least 5, 10, 25, 50, 100, 500, or 1000 fold higher than its EC50 forEDG-l/SlP-1. Thus, some of the EDG-1/SIP-1 modulatory compounds will have an EC50 for EDG-I/S1 P-l that is less than 5 nM while their EC50 for one or more of the other EDG/S 1P receptors are at least 100 nM or higher. Other than assaying binding activity to the EDG/S IP receptors, EDG-1/S1P-1 selective agents can also be identified by examining a test agent's ability to modify a cellular process or activity mediated by an EDG/S 1P receptor. [0042] The compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by lymphocytes interactions, for example in transplantation, such as acute or chronic rejection of cell, tissue or organ alio- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g. rheumatoid arthR1tis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoR1asis, Graves ophthalmopathy, alopecia areata and others, allergic diseases, e.g. allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis, inflammatory diseases optionally with underlying aberrant reactions, e.g. inflammatory bowel disease, Crohn's disease or ulcerative colitis, intR1nsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthR1tis, irR1tant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, myocarditis or hepatitis, ischemia/reperfusion injury, e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, traumatic shock, T cell lymphomas or T cell leukemias, infectious diseases, e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic bacteR1al infection, or senile dementia. Examples of cell, tissue or solid organ transplants include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus. For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. [0043] Furthermore, the compounds of formula I are useful in cancer chemotherapy, particularly for cancer chemotherapy of solid tumors, e.g. breast cancer, or as an anti-angiogenic agent. [0044] The required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration compR1se from ca. I to 50 mg active ingredient. [0045] The compounds of Formula I can be administered by any conventional route, in particular enterally, for example, orally, e.g. in the form of tablets or capsules, or parenterally, for example, in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Pharmaceutical compositions compR1sing a compound of Formula 1 in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carR1er or diluent can be manufactured in conventional manner by mixing with a pharmaceutical^ acceptable carR1er or diluent. (0046] The compounds of Formula I can be administered in free form or in pharmaceutically acceptable salt form, for example, as indicated above. Such salts can be prepared in a conventional manner and exhibit the same order of activity as the free compounds. [0047] In accordance with the foregoing the present invention farther provides: [0048] 1.1 A method for preventing or treating disorders or diseases mediated by lymphocytes, e.g. such as indicated above, in a subject in need of such treatment, which method compR1ses administeR1ng to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; [0049] 1.2 A method for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment, which method compR1ses administeR1ng to said subject an effective amount of a compound of formula I or a pharmaceutical ly acceptable salt thereof; [0050] 1.3 A method for inhibiting or controlling deregulated angiogenesis, e.g. sphingosine-1-phosphate (SIP) mediated angiogenesis, in a subject in need thereof, compR1sing administeR1ng to said subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. [0051] 1.4 A method for preventing or treating diseases mediated by a neo- angiogenesis process or associated with deregulated angiogenesis in a subject in need thereof, compR1sing administeR1ng to said subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. [0052] 2. A compound of formula I, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical, e.g. in any of the methods as indicated under 1.1 to 1.4 above. [0053] 3. A pharmaceutical composition, e.g. for use in any of the methods as in l.l to 1.4 above compR1sing a compound of formula I in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carR1er therefor. [0054] 4, A compound of formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in any of the method as in I.I to 1.4 above. [0055} The compounds of formula I may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of alio- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g. a malignant cell antiproliferative agent. For example the compounds of formula I may be used in combination with a calcineuR1n inhibitor, e.g. cyclospoR1n A or FK 506; a mTOR inhibitor, e.g. rapamycin, 40-0(2-hydroxyethy!)-rapamycin, CCI779, ABT578 or AP23573; an ascomycin having immunosuppressive properties, e.g. ABT-28I, ASM981, etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoR1bine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergua!ine or an immunosuppressive homologue, analogue or deR1vative thereof; immunosuppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40. CD45, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y ; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent. [0056] By the term "chemotherapeutic agent" is meant any chemotherapeutic agent and it includes but is not limited to, [0057] i. an aromatase inhibitor, [0058] ii. an anti-estrogen, an anti-androgen (especially in the case of prostate cancer) or a gonadorelin agonist, [0059] iii. a topoisomerase I inhibitor or a topoisomerase II inhibitor, [0060] iv. a microtubule active agent, an alkylating agent, an antineoplastic antimetabolite or a platin compound, [0061] v. a compound targeting/decreasing a protein or lipid kinase activity or a protein or lipid phosphatase activity, a further anti-angiogenic compound or a compound which induces cell differentiation processes, [0062] vi. a bradykinin 1 receptor or an angiotensin II antagonist, [0063] vii. a cyclooxygenase inhibitor, a bisphosphonate, a histone deacetylase inhibitor, a heparanase inhibitor (prevents heparan sulphate degradation), e.g. PI-88, a biological response modifier, preferably a lymphokine or interferons, e.g. interferon y, an ubiquitination inhibitor, or an inhibitor which blocks anti-apoptotic pathways, [0064] viii. an inhibitor of Ras oncogenic isoforms, e.g. H-Ras, K-Ras or N-Ras, or a farnesyl transferase inhibitor, e,g. L-744,832 or DK8G557, [0065] ix. a teiomerase inhibitor, e.g. telomestatin, [0066] x. a protease inhibitor, a matR1x metalloproteinase inhibitor, a methionine aminopeptidase inhibitor, e.g. bengamide or a deR1vative thereof, or a proteosome inhibitor, e.g. PS-341, and/or [0067] xi. a mTOR inhibitor. [0068] The term "aromatase inhibitor" as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyR1doglutethimide, tR1lostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. A combination of the invention compR1sing a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors. [0069] The term "anti-estrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloR1de. A combination of the invention compR1sing a chemotherapeutic agent which is an anti-estrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors. [0070] The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide. [0071] The term "gonadorelin agonist" as used herein includes, but is not limited to abaretix, goserelin and goserelin acetate. [0072] The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topotecan, iR1notecan, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound Al in WO99/17804). [0073] The term "topoisomerase II inhibitor" as used herein includes, but is not limited to the anthracyclines such as doxorubicin, daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. [0074] The term "microtubule active agent" relates to microtubule stabilizing and microtubule destabilizing agents including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincR1stine especially vincR1stine sulfate, and vinorelbine, discodermolides and epothilones and deR1vatives thereof, e.g. epothilone B or a deR1vative thereof. [0075] The term "alkylating agent" as used herein includes, but is not limited to busulfan, chlorambucil, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadei™). [0076] The term "antineoplastic antimetabolite" includes, but is not limited to 5- fluorouracil, capecitabine, gemcitabine, cytarabine, fludarabine, thioguanine, methotrexate and edatrexate. [0077] The term "platin compound" as used herein includes, but is not limited to carboplatin, cis-platin and oxaliplatin. [0078] The term "compounds targeting/decreasing a protein or lipid kinase activity or further anti-angiogenic compounds" as used herein includes, but is not limited to protein tyrosine kinase and/or seR1ne and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g. compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers), the vascular endothelial growth factor family of receptor tyrosine kinases (VEGFR), the platelet-deR1ved growth factor-receptors (PDGFR), the fibroblast growth factor-receptors (FGFR), the insulin-iike growth factor receptor I (IGF-1R), the Trk receptor tyrosine kinase family, the Axl receptor tyrosine kinase family, the Ret receptor tyrosine kinase, the Kit/SCFR receptor tyrosine kinase, members of the c-Abl family and their gene-fusion products (e.g. BCR-Abl), members of the protein kinase C (PKC) and Raf family of seR1ne/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK or PI(3) kinase family, or of the Pl(3)-kinase-related kinase family, and/or members of the cyclin-dependent kinase family (CDK) and anti-angiogenic compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition. {00791 Compounds which target, decrease or inhibit the activity of VEGFR are especially compounds, proteins or antibodies which inhibit the VEGF receptor tyrosine kinase, inhibit a VEGF receptor or bind to VEGF, and are in particular those compounds, proteins or monoclonal antibodies geneR1cally and specifically disclosed in WO 98/35958, e.g. l-(4-chloroaniiino)-4-(4-pyR1dylmethyI)phthalazine or a pharmaceutically acceptable salt thereof, e.g. the succinate, in WO 00/27820, e.g. a N-aryl(thio) anthranilic acid amide deR1vative e.g. 2-[(4-pyR1dyl)methyi]amino-N-[3-methoxy-5-(tR1fIuoromethyl)phenyi]benzamide or 2-[(l-oxido-4-pyR1dyI)methyI]amino-N-[3-tR1fluoromethylphenyl]benzamide, or in WO 00/09495, WO 00/59509, WO 98/11223, WO 00/27819 and EP 0 769 947; those as descR1bed by M. Prewett et al in Cancer Research 52 (1999) 5209-5218, by F. Yuan et al in Proc. Natl. Acad. Sci. USA, vol. 93, pp. I4765-I4770, Dec. 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti et al in Toxicologic Pathology, Vol. 27, no. 1, pp 14-21, 1999; in WO 00/37502 and WO 94/10202; Angiostatin™, descR1bed by M. S. O'Reilly et al, Cell 79, 1994, 315-328; Endostatin™, descR1bed by M. S. O'Reilly et ai, Cell 88,1997,277-285; anthranilic acid amides; ZD4190; ZD6474; SU5416; SU6668; or anti-VEGF antibodies or anti-VEGF receptor antibodies,e.g. RhuMab. [0080} By antibody is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. (0081] Compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g. EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, or which have a dual inhibiting effect on the ErbB and VEGF receptor kinase and arc in particular those compounds, proteins or monoclonal antibodies geneR1cally and specifically disclosed in WO 97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/30347 (e.g. compound known as CP 358774), WO 96/33980 (e.g. compound ZD 1839) and WO 95/03283 (e.g. compound ZM105180) or PCT/EP02/08780; e.g. trastuzumab (HerpetinR), cetuximab, Iressa, OSI-774, CI-1033, EKB- 569, GW-2016, El.I, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3. [0082] Compounds which target, decrease or inhibit the activity of PDGFR are especially compounds which inhibit the PDGF receptor, e.g. a N-phenyI-2-pyR1midine-amine deR1vative, e.g. imatinib. [0083] Compounds which target, decrease or inhibit the activity of c-Abl family members and their gene fusion products are, e.g. aN-phenyl-2-pyR1midine-amine deR1vative, e.g. imatinib; PD180970; AG957; or NSC 680410. [0084] Compounds which target, decrease or inhibit the activity of protein kinase C, Raf, MEK, SRC, JAK, FAK and PDK family members, or PI(3) kinase or Pl(3) kinase- related family members, and/or members of the cyclin-dependent kinase family (CDK) are especially those staurospoR1ne deR1vatives disclosed in EP 0 296 110, e.g. midostauR1n; examples of further compounds include e.g. UCN-01, safingol, BAY 43-9006, Bryostatin 1, PeR1fosine; Ilmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; or LY333531/LY379196. [0085] Further anti-angiogenic compounds are e.g. thalidomide (THALOM1D) andTNP-470. [0086] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g, inhibitors of phosphatase I, phosphatase 2A, PTEN or CDC25, e.g. okadaic acid or a deR1vative thereof. [0087] Compounds which induce cell differentiation processes are, e.g. retinoic acid, a-, y- or 5-tocopherol or a-, y: or 5-tocotR1enol. [0088] The term cyclooxygenase inhibitor as used herein includes, but is not limited to, e.g. celecoxib (CelebrexR), rofecoxib (VioxxR), etoR1coxib, valdecoxib or a 5-aIkyl-2-aryiaminophenylacetic acid, e.g. 5-methyI-2-(2'~chloro-6'-fluoroaniIino)phenyl acetic acid. [0089] The term "histone deacetylase inhibitor" as used herein includes, but is not limited to MS-27-275, SAHA, pyroxamide, FR-901228 or valproic acid. [0090) The term "bisphosphonates" as used herein includes, but is not limited to, etR1donic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, R1sedronic and zoledronic acid. [0091J The term "matR1x metalloproteinase inhibitor" as used herein includes, but is not limited to collagen peptidomimetic and non-petidomimetic inhibitors, tetracycline deR1vatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue maR1mastat, pR1nomastat, BMS-279251, BAY 12-9566, TAA211 or AAJ996. [0092] The term "mTOR inhibitor" as used herein includes, but is not limited to rapamycin (sirolimus) or a deR1vative thereof, e.g. 32-deoxorapamycin, I6-pent-2-ynyloxy- 32-deoxorapamycin, 16-pent-2-ynyloxy-32(S)-dihydro-rapamycin, 16-pent-2-ynyloxy- 32(S)-dihydro-40-O-(2-hydroxyethyI)-rapamycin and, more preferably, 40-0-(2-hydroxy- ethyl)-rapamycin. Further examples of rapamycin deR1vatives include e.g. CCI779 or 40- [3- hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin or a pharmaceutical^ acceptable salt thereof, as disclosed in USP 5,362,718, ABT578 or 40-(tetrazoly!)- rapamycin, particularly 40-epi-(tetrazolyl)-rapamycin, e.g. as disclosed in WO 99/15530, or rapalogs as disclosed e.g. in WO 98/02441 and WO01/14387, e.g. AP23573. [0093] Where the compounds of formula I are administered in conjunction with other immunosuppressive / immunomodulatory, anti-inflammatory or chemotherapeutic therapy, dosages of the co-administered immunosuppressant, immunomodulatory, antiinflammatory or chemotherapeutic compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a calcineuR1n inhibitor, on the specific drug employed, on the condition being treated and so forth. [0094] In accordance with the foregoing the present invention provides in a yet further aspect: [0095] 5. A method as defined above compR1sing co-administration, e.g. concomitantly or in sequence, of a therapeutically effective non-toxic amount of a compound of formula I and at least a second drug substance, e.g. an immunosuppressant, immuno modulatory, anti-inflammatory or chemotherapeutic drug, e.g. as indicated above. [0096J 6. A pharmaceutical combination, e.g. a kit, compR1sing a) a first agent which is a compound of formula 1 as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent, e.g. an immunosuppressant, immunomodulatory, anti-inflammatory or chemotherapeutic drug, e.g. as disclosed above. The kit may compR1se instructions for its administration, [0097] The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessaR1ly administered by the same route of administration or at the same time. [0098] The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients. Methods for PrepaR1ng Compounds of the Invention [0099] The present invention also includes processes for the preparation of immunomodulatory compounds of the invention. In the reactions descR1bed, it can be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991. [00100] Compounds of Formula I, in which A is 2-carboxy-ethyI, can be prepared [00101] in which B, E, X, Y, R, R2, R3, R4 and R5 are as defined for Formula I above. Compounds of Formula I can be prepared sequentially by treating a compound of formula 2 with a suitable acid (e.g. TFA, and the like), reacting with f-butyl acrylate in the presence of a suitable amine (e.g. DIEA, and the like) and removing the /-butyl protecting group with a suitable acid (e.g. TFA, and the like). The reaction proceeds at a temperature of about 0 to about 120°C and can take up to about 24 hours to complete. [00102] Compounds of Formula I, in which A is l//-tetrazoI-5-ylalkyl, can be [00103] in which B, E, X, Y, R] R2, R3, R4 and R5 are as defined for Formula I above, Z is 0 or 1. Compounds of Formula I can be prepared sequentially by treating a compound of formula 2 with a suitable acid (e.g. TFA, and the like), reacting with acryionitR1le or bromoacetonitR1le in the presence of a suitable base (e.g. NaOAc, and the like) and followed by reacting with NaN3 in a suitable solvent (e.g. DMF, and the like). The reactions proceed at a temperature of about 0 to about I20°C and can take up to about 24 hours to complete. [00104] More details of the synthesis of compounds of Formula ! are descR1bed in the Example, infra. Additional Processes for PrepaR1ng Compounds of the Invention: [00105] A compound of the invention can be prepared as a pharmaceutical ly acceptable acid addition salt by reacting the free base form of the compound with a pharmaceuticaliy acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceuticaliy acceptable inorganic or organic base. Alternatively, the salt forms of the compounds of the invention can be prepared using salts of the starting mateR1als or intermediates. [00106] The free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively. For example a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloR1c acid, etc.). [00107] Compounds of the invention in unoxidized form can be prepared from N- oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, tR1phenyl phosphine, lithium borohydR1de, sodium borohydR1de, phosphorus tR1chloR1de, tR1bromide, or the like) in a suitable inert organic solvent (e.g. acetonitR1le, ethanol, aqueous dioxane, or the like) at 0 to 80°C. [00108] Prodrugs deR1vatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropR1ate prodrugs can be prepared by reacting a non-deR1vatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyIoxyalkylcarbanochloR1date, para-nrtrophenyl carbonate, or the like). [00109] Protected deR1vatives of the compounds of the invention can be made by means known to those of ordinary skill in the art. A detailed descR1ption of techniques applicable to the creation of protecting groups and their removal can be found in T W. Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc., 1999. [00110] Compounds of the present invention can be conveniently prepared, or , formed duR1ng the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystatlization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol. [00111] Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to forma pair of diastereoisomeR1c compounds, separating the diastereomers and recoveR1ng the optically pure enantiomers. While resolution of enantiomers can be carR1ed out using covalent diastereomeR1c deR1vatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeR1c salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilaR1ties. The diastereomers can be separated by chromatography, or preferable, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in 4 racemization. A more detailed descR1ption of the techniques applicable to the resolution of stereoisomers of compounds from the their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981. [00112] In summary, the compounds of Formula I can be made by a process, which involves: [00113] (a) reacting a compound of formula 2 with either /-butyl acrylate, acylonitR1le/NaNs or bromoacetonitR1le/NaNa; and [00114] (b) optionally converting a compound of the invention into a pharmaceutical ly acceptable salt; [00115] (c) optionally converting a salt form of a compound of the invention to a non-salt form; [00116] (d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide; [00117] (e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form; (00118] (f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; [00119] (g) optionally converting a non-deR1vatized compound of the invention into a pharmaceutically acceptable prodrug deR1vative; and [00120] (h) optionally converting a prodrug deR1vative of a compound of the invention to its non-deR1vatized form. [00121] Insofar as the production of the starting mateR1als is not particularly descR1bed, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter. [00122] One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used. EXAMPLES [00123] The following examples provide detailed descR1ptions of the preparation of representative compounds and are offered to illustrate, but not to limit the present invention. [00124] To a solution of 4-bromo-3-methyl-phenol (500 mg, 2.67 mrnol, I eq.) in acetonitR1le (5 mL) is added K2CO3 (1.47 g, 10,6 mrnol, 4 eq.). The mixture is stirred for 30 minutes at room temperature. lodomethane (493 mg, 1.3 eq) is then added dropwise via syR1nge and the mixture is stirred for 12 hours. The reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic layers are washed with bR1ne and dR1ed over Na2So4. After concentration, the residue is puR1fied by silica gel column chromatography (5% EtOAc in hexanes) to give l-Bromo-4-methoxy-2-methyI-benzene. [00125] l-Bromo~4-methoxy-2-methyl-benzene (520 mg, 2.6 mrnol) is dissolved in cyclohexylzinc bromide THF solution (0.5 M, 15 mL) in a microwave tube. Pd(/-Bu3P)2 (66 mg, 0.13 mrnol, 0.05 eq.) is added to this solution. The mixture is purged with N: (g) for 5 minutes and heated at 100°C for 30 minutes using microwave irradiation. Upon completion, the reaction mixture is diluted with EtOAc, washed with IN HC1 (aq), bR1ne, filtered through cclite, and dR1ed over Na2So4. After concentration, the residue is partially puR1fied by silica gel chromatography (5% EtOAc in hexanes) to give crude 1 -cydohexyl-4-methoxy-2-methyl-benzene. [00126] To a solution of crude l-cyclohexyl-4-methoxy-2-methyl-benzene in dry DCM (10 mL) is added BBr3 at -78°C. Following this addition, the mixture is heated at 50°C for 12 hours. The reaction mixture is cooled in an ice bath, and the reaction is quenched by the dropwise addition of water. The mixture is extracted with DCM. The combined organic phases are washed with 10 % NaHCCb (aq), bR1ne, and dR1ed over Na2So4. After concentration, the residue is puR1fied by silica gel chromatography (10% EtOAc in hexanes) to give 4-cyclohexyI-3-methyI-phenoI. [00127] To a solution of 4-(4-carboxy-pheny!)-pipeR1dine-i-carboxylic acid tert- butyl ester (2 g, 6.5 mrnol) in dry THF (50 mL) is added BH3Me2S complex (3.1 mL, 5 eq.) at 0°C under N2 (g). The mixture is warmed to room temperature and stirred for 2 hours. The mixture is then heated at 60°C for 15 minutes to complete the reaction. The reaction mixture is cooled in an ice bath and quenched by the slow addition of water (50 mL). The mixture is extracted with EtOAc (3 x 40 mL), The combined organic layers are washed with saturated NaHCOj (aq), bR1ne, and dR1ed over Na2So4. After concentration, the crude residue, 4-(4-hydroxymethyl-phenyI)-pipeR1dine-1-carboxylic acid tert-butyl ester, is directly used in the next step without further puR1fication. (00128] To a mixture of 4-cycIohexyi-3-methyl-phenoI (65 mg, 0.34 mrnol, 1 eq.), 4-(4-Hydroxymethyl-phenyI)-pipeR1dine-l-carboxyIic acid tert-butyl ester (100 mg, 0,34 mrnol, 1 eq.) and PPh3(134mg, 0.51 mrnol, 1.5 eq.) in dry DCM (3 mL) is added 1,T-(azodicarbonyl)-dipippeR1dine (129 mg, 0.51 mrnol, 1.5 eq.) in DCM (1 mL), The mixture is stirred at room temperature for 12 hours. After concentration, the residue is puR1fied by silica gel chromatography (10% EtOAc in hexanes) to give 4-[4-(4-cyclohexyl-3-methyl- phenoxymethyl)-phenyI]-pipeR1dine-l-carboxyiic acid tert-butyl ester. [00129] A solution of4-[4-(4-cyciohexyl-3-methyl-phenoxymethyl)-phenyl]- pipeR1dine-1-carboxyiic acid tert-butyl ester (127 mg, 0.27 mmol) in DCM/TFA (1:2 v/v, 3 mL) is stirred for 40 minutes. After concentration, the residue obtained is dissolved in methanol (2 mL). DIEA (130 µL, 1.36 mmol, 5 eq.) and r-butyl acrylate (80 µL, 0.54 mmol, 2 eq.) are added to this solution. The reaction mixture is heated at 90°C for 30 minutes using microwave irradiation. After concentration, the residue is puR1fied by silica gel chromatography (40% EtOAc in hexanes) to give 3-{4-[4-(4-cycIohexyl-3-methyI-phenoxymethyl)-phenyl]-pipeR1din-l-yl}-propionic acid tert-butyl ester. This mateR1al is dissolved in DCM/TFA (1:1 v/v, 3 mL), and the solution is stirred at room temperature for 40 minutes. After concentration, the crude product is puR1fied by preparative RP LC-MS to give3-{4-[4'(4"CVclohexyl-3-methyl-phenoxymethylVphenyl-1-piperidin-l-yl)-propionic acid: !H NMR (CD3OD, 400 MHz) 5 7.41(d, 2H, J= 8 Hz), 7.28 (d, 2H, J= 8 Hz), 7.08(m, 1H), 6.75-6.73 (2H), 5.01 (s, 2H), 3.69 (d, 2H, J = 10 Hz), 3.46 (t, 2H, J= 7 Hz), 3.18(m, 2H), 2.95 m, 1H), 2.86 (t, 2H, j= 7 Hz), 2.65 (m, IH), 2.27 (s, 3H)S 2.18 (m, 2H), 2.04-1.70 (7H), 1.46-1.30 (5H); MS (ES+): (436.3, M+l)+. [00130} To a solution of 4-chloro-3-(tR1fluoromethyl)benzyl alcohol (2.87 g, 13.63 mmol) in DMF (40 mL) is added sodium hydR1de (60% in mineral oil, 654 mg, 16.36 mmol) at 0 °C and the reaction mixture is stirred at 0 °C for 30 minutes. 4-methoxy-benzyl chloR1de (2.35 g, 15 mmol) in DMF (10 mL) is added and the reaction mixture is stirred at 0 °C for 1 h and at room temperature for 3 hours. The reaction mixture is poured into saturated aqueous NH4CI (300 mL) and extracted with EtOAc. The combined extracts are washed with bR1ne (2 * 80 mL) and dR1ed overNa2So4. After concentration, the residue is puR1fied by silica gel chromatography (8:1 hexanes/EtOAc) to give l-Chloro-4-(4-methoxy-benzyloxymethyl)-2-tR1fluoromethyI-benzene. [00131] l-Chloro-4-(4-methoxy-benzylox>methyI>2-tR1fluoromethyl-benzene (2 g, 6.51 mmol), Pd(f-Bu3P)2 (66.54 mg, 0.13 mmol) and cyclohexylzinc bromide/THF solution (0.5 M, 40 mL, 19.5 mmol) are mixed in l-methyI-2-pyrrolidinone (NMP) (40 mL). The mixture is purged with N2 (g) and then heated at 105 °C for 16 hours. The reaction mixture is poured into saturated aqueous NH4C1 (250 mL) and extracted with EtOAc. The combined extracts are washed with bR1ne and dR1ed overNa2So4. After concentration, the residue is puR1fied by silica gel chromatography (8:1 hexanes/EtOAc) to give l-Cyclohexyl-4-(4-methoxy-benzyloxymethyl)-2-tR1fluoromethyl-benzene. To a solution of this mateR1al in DCM (8 mL) is added TFA (8 mL). The reaction mixture is stirred at room temperature for 16 hours. After concentration, the residue is partitioned between saturated aqueous NH4CI and EtOAc. The aqueous phase is extracted with EtOAc. The combined organic extracts are washed with bR1ne and dR1ed over Na2So4 After concentration, the residue is puR1fied by silica gel chromatography (4:1 hexanes/EtOAc) to give (4-CycIohexyl-3-tR1fluoromethyl-phenyI)-methanol. [00132] To a solution of (4-cyclohexyl-3-tR1fluoromethyl-phenyl)-methanol (258 mg, 1.0 mmol) in DMF (7 mL) is added sodium hydR1de (60% in mineral oil, 60 mg, 1.5 mmol) at 0 °C and the reaction mixture is stirred at 0 °C for 30 minutes. After the addition of a solution of 2-chIoro-5-bromopyR1dtne (231 mg, 1.2 mmol) in DMF (3 mL), the reaction mixture is stirred at 0 °C for 1 h and at room temperature for 18 hours. The reaction mixture is poured into saturated aqueous NH4CI and extracted with EtOAc. The combined extracts are washed with bR1ne and dR1ed over Na2So4 After concentration, the residue is puR1fied by silica gel chromatography (19:1 hexanes/EtOAc) to give 5-Bromo-2-(4-cyclohexyl-3-tR1fluoromethyI-benzyloxy)-pyR1dine. [00133] 5-Bromo-2-(4-cyclohexyl-3-tR1fluoromethy!-ben2yloxy)-pyR1dine(332mg, 0.8 mmol), ter/-butyi 1-piperazine-carboxylate (178 mg, 0.96 mmol), Pd(dppf)Cl2 (17.5 mg, 0.024 mmol), dppf (20 mg, 0.036 mmol) and sodium rerr-butoxide (115 mg, 1.19 mmol) are mixed in toluene (2 mL). The mixture is purged with N2 (g), heated at 80 °C for 14 h, poured into saturated aqueous NaHCo3 and extracted with EtOAc. The combined extracts are washed with bR1ne and dR1ed over Na2So4. After concentration, the residue is puR1fied by silica gel chromatography (180:25:1 hexanes/EtOAc/Et3N) to give 4-[6-(4-Cyclohexyl-3- tR1fluoromethyI-benzyloxy)-pyR1din-3-yl]*piperazine-l-carboxylic acid tert-butyl ester. (00134J To a solution of 4-[6-(4-Cyclohexyl-3-tR1fluoromethyl-benzyloxy)-pyR1din- 3-yl]-piperazine-l-carboxylic acid tert-butyl ester (155 mg, 0.398 mmol) in DCM (2 mL) is added tR1fluoroacetic acid (TFA) (4 mL). The reaction mixture is stirred at room temperature for 30 minutes and evaporated to dryness- The residue obtained is mixed with /ert-butyl acrylate (76 mg, 0.6 mmol) and DIEA (193 mg, 1.49 mmol) in MeOH (4 mL) and the mixture is heated in a microwave oven at 90 C for 30 minutes. The reaction mixture is poured into saturated aqueous NaHCCh and extracted with EtOAc. The combined extracts are washed with bR1ne and dR1ed over Na2So4 After concentration, the residue is puR1fied by silica gel chromatography (150:50:1 hexanes/EtOAc/Et3N) to give 3-{4-[6-(4-Cyciohexy!-3-tR1fluoromethyl-benzyloxy)-pyR1din-3-yl]-piperazin-l-yl}-propionic acid tert-butyl ester. This mateR1al is dissolved in DCM/TFA (1:1 v/v, 2 mL), and the solution is stirred at room temperature for 1 hour. After concentration, the crude product is puR1fied by preparative RP LC-MS to give lHNMR(CD3OD): 1.28-1.85 (I0H), 2.88 (t,7= 6.2 Hz, 2H), 2.90 (m, 1H), 3.15-3.85 (8H), 3.69 (t, J= 6.2 Hz, 2H), 5.42 (s, 2H)5 7.38 (br, 1H), 7.57 (d,J-7Hz, lH),7.65(d,J=7Hz, 1H), 7,71 (s, 5H), 7.91 (s, lH),8.05(br, 1H);ES1-MS m/z 492.2 (MH*). [00135] 2,5-DibromopyR1dine (10 mmol), Pd(Ph3P)4 (0.3 mmol) and zinc cyanate (10 mmol) are mixed in DMF (12 mL) and purged with N2. The mixture is heated in a microwave reactor at 135 °C for 15 minutes, poured into saturated NH4CI solution, and extracted with EtOAc. The combined extracts are washed with saturated aqueous NaC! and dR1ed overNa2So4 After concentration, the residue is puR1fied by silica gel chromatography (9:1 hexanes/EtOAc) to give 5-bromo-pyR1dine-2-carbonitR1le. [00136] 5-Bromo~pyR1dine-2-carbonitR1le (8 mmol), /erf-butyl l-piperazine- carboxylate (9.6 mmol), Pd(dppf)Cl2 (0.24 mmol), dppf (0.36 mmol) and sodium terh butoxide (11.9 mmol) are mixed in toluene (12 mL) and purged with N2. The mixture is heated in a microwave reactor at 120 °C for 15 minutes, poured into saturated Na2CO3 solution and extracted with EtOAc. The combined extracts are washed with saturated aqueous NaCl and dR1ed over Na2So4 After concentration, the residue is puR1fied by silica gel chromatography (2:1 hexanes/EtOAc) to give tert-buty\ 4-(6-cyano-pyR1din-3-yl)-piperazine-1 -carboxylate. [00137] To a solution of ferf-butyl 4-(6-cyano-pyR1din-3-yl)-piperazine-l- carboxylate (2.15 mmoi) in THF (20 mL) is added a solution of D1BAL-H in THF (1.0 M, 13 mmol) dropwise and the reaction mixture is stirred at room temperature for 15 minutes. After it is cooled to 0 °C, the reaction mixture is mixed with a solution of aqueous HCI (2 N, 5 mL) after which the reaction mixture is partitioned between saturated Na2Co3 solution and EtOAc. The aqueous phase is extracted with EtOAc. The combined organic extracts are washed with saturated aqueous NaCl and dR1ed over Na2So4 After concentration, the residue is puR1fied by silica gel chromatography (3:7 hexanes/EtOAc) to give (ert-buty\ 4-(6-formyl-pyR1din-3-yl)-piperazine-l -carboxylate. [00138] To a solution of tert-buty\ 4-(6-formyl-pyR1din-3-yl)-piperazine-l- carboxylate (0.39 mmol) in THF (10 mL) is added NaBH4 (2.72 mmol) and the reaction mixture is stirred at room temperature for 1 hour. After it is cooled to 0 °C, the reaction mixture is slowly mixed with ice cold water (5 mL) and then partitioned between saturated Na2Co3 solution and ] 0% MeOH in EtOAc. The aqueous phase is extracted with 10% MeOH in EtOAc. The combined organic extracts are washed with saturated aqueous NaCI and dR1ed overNa2So4 After concentration, the residue is puR1fied by silica gel chromatography (100/10/1 EtOAc/MeOH/Et3N) to give ten-butyl 4-(6-hydroxymethyl-pyR1din-3-yl)-piperazine-1 -carboxylate. {00139] tert-Butyl4-(6-hydroxymethyl-pyR1din-3-yl)-pipera2ine-l-carboxylate (0.22 mmol), 4-CycIohexyl-3-tR1fluoromethyl-phenol (0.22 mmol, synthesized in a similar manner as descR1bed in a previous example), l,1-azodicarbonyl dipiperdine (0.33 mmol) and PhjP (0.33 mmol) are mixed in DCM (2 mL). The reaction mixture is stirred at room temperature for 17 h and then partitioned between saturated Na2Co3 solution and EtOAc. The aqueous phase is extracted with EtOAc. The combined organic extracts are washed with saturated aqueous NaCI and dR1ed over Na2So4 After concentration, the residue is puR1fied by silica gel chromatography (6:5 hexanes/EtOAc) to give ten-butyl 4-[6-(4-cyclohexyI-3- tR1fluoromethyl-phenoxymethyl)-pyR1din-3-yl]-piperazine-l-carboxylate. (00140] To a solution of tert-butyl 4-[6-(4~cyclohexyI-3-tR1fluoromethyl- phenoxymethyI)-pyR1din-3-yI]-piperazine-l-carboxylate (0.021 mmol) in DCM (1 mL) is added tR1fluoroacetic acid (2 mL). The reaction mixture is stirred at room temperature for 1 hour and evaporated to dryness. The residue is mixed with tert-butyl acrylate (0.3 mmol) and DIEA (0.6 mmol) in MeOH (1.5 mL). The mixture is heated in a microwave oven at 90 "C for 30 minutes and evaporated to dryness. To a solution of the residue in DCM (1.5 mL) is added tR1fluoroacetic acid (1.5 mL). The reaction mixture is stirred at room temperature for 1 hour. After concentration, the crude residue is puR1fied by preparative RP LC-MS to give 3z 2.80(t,J=6.8Hz,2H), 3.37-3.78 (8H), 3.43 (t,J= 6.8 Hz, 2H), 5.16 (s,2H), 7.13 (dd,J = 8.4,2.8 Hz, IH),7.!5(s, 1H), 7.39 (d, 7- 8.4 Hz, IH), 7.66 (d, 7= 8.8 Hz, 1H), 7.75 (dd,J = 8.8, 2.8 Hz, 1H), 8.30 (s, 1H); ESI-MS mfz 492.2 (MH*). [00141] To a solution of l-Bromo-4-methoxy-2-tR1fluoromethyl-benzene (500 mg, 1.961 mmol) in 1,4-dioxane (8 mL) is added sequentially: pipeR1dine (2 eq., 3.921 mmol, 0.41 mL), Pd2dba3 (2 moi%, 0.039 mmol, 36 mg), K'OBu (1.5 eq., 2.941 mmol, 330 mg) and l,3-(Bis(236-di-wo-propylphenyl)-imidazolium chloR1de (iPrHCl, 4 mol%, 0.078 mmol, 33 mg). The resulting reaction mixture is heated in a sealed tube at 150°C oil bath for 12 hours. After cooling to room temperature, the reaction mixture is concentrated. The residue obtained is partially puR1fied by silica gel chromatography (9:1 hexanes/EtOAc) to give crude 1 -(4-Methoxy-2-tR1fluoromethyl-phenyl)-pipeR1dine. [00142] To a solution of crude l-(4-Methoxy-2-tR1fluoromethyl-phenyl)-pipeR1dine in dry DCM (3 mL) cooled to -78°C is added BBr3 (1M in DCM, 3 eq., 1.2 mL). Following this addition, the cooling bath is removed and the reaction is stirred at 25 °C for 12 hours. Upon completion, the reaction is cooled in an ice bath, and water is added dropwise. The quenched reaction is basified to pH=8 by the slow addition of 10 % NaHC(>j (aq). The reaction mixture is diluted with QCM and washed with H2O followed by saturated aqueous NaCl. The organic solution is dR1ed over Na2SO4 After concentration, the residue is puR1fied by silica gel chromatography (3:1 hexanes/EtOAc) to give 4-PipeR1din-l-yl-3-tR1fluoromethyl-phenol. [MS: (ES*) 246.1 (M+1)*]. [00143] Mitsunobu coupling of 4-(4-hydroxymethyI-phenyI)-pipeR1dine-I- carboxylic acid tert-butyl ester and 4-PipeR1din-l-yI-3-trifluoromethyl-phenoI, followed by: Boc deprotection, alkylation with /-butyl acrylate, t-butyl ester deprotection, and final RP LC-MS puR1fication as descR1bed in a previous example gave 3-(4-f4-f4-pipeR1din-l-vl-3- tR1fluoromethyl-phenoxymethyn-phcnyn-piperidin-l-yl)-Dropionicacid as a tan solid. 1H NMR (DMSO-d6) 400 MHz) 8 10.25 (bs, IH), 7.49(d, 1H), 7.41 (d, 2H), 7.27 (d, 2H), 7.30-7.20 (m, 2H), 5.10 (s, 2H), 3.61-3.52 (m, 2H), 3.36-3.26 (m, 2H), 3.14-3.02 (m, 2H), 2.90-2.80 (m, 3H), 2.78-2.72 (m, 4H), 2.03-1.94 (m, 4H), 1.65-1.55 (m, 4H), 1.53-1.45 (m, 2H); MS (ES+): (491.2, M+l)+. {00144] Mitsunobu coupling of 4-Bromo-3-methyl-phenoI and 4-(4- Hydroxymethyl-phenyI)-pipeR1dine-l-carboxylic acid tert-butyl ester as descR1bed in a previous example gave 4-[4-(4-Bromo-3-methyl-phenoxymethyl)-phenyl]-pipeR1dine-l-carboxylic acid tert-butyl ester. [00145] To a solution of 4-[4-(4-Bromo-3-methyl-phenoxymethyI)-phenyl]- pipeR1dine-1-carboxylic acid tert-butyl ester (409 mg, 0.8884 mmol) in dry THF (5 mL) cooled to -78 °C is added n-BuLi (1.6 M in hexanes, 1.1 eq., 0.9772 mmol, 0.61 mL). The resulting mixture is stirred at -78 °C for 30 minutes and a solution of tetrahydro-thiopyran-4-one(l.l eq., 0.9772 mmol, 114 mg) in dry THF (0.5 mL) is then added dropwise. After 30 minutes, the reaction mixture is quenched with saturated aqueous NH4CI and warmed to room temperature. The reaction mixture is diluted with EtOAc and washed sequentially with H2O and saturated aqueous NaCI. The organic solution is dR1ed over Na2So4. After concentration, the residue is partially purified by silica gel chromatography (3:1 hexanes/EtOAc) to give crude 4-{4-[4-(4-Hydroxy-tetrahydro-thiopyran-4-y!)-3-methyI~ phenoxymethyl]-phenyl}-pipeR1dine-l-carboxylic acid tert-butyl ester. [00146] To a solution of crude 4-{4-[4-(4-Hydroxy-tetrahydro-thiopyran-4-yl)-3- methyl-phenoxymethyl]-phenyl}-pipeR1dine-l-carboxylic acid tert-butyl ester in dry DCM (7 mL) is added tR1ethyl si lane (4.442 mmol, 517 mg, 0.71 mL) followed by TFA (7 mL). The resulting mixture is stirred at room temperature for 2 hours. After concentration, the crude residue, 4-{4-[3-MethyI-4-(tetrahydro-thiopyran-4-yl)-phenoxymethy]]-phenyl}-pipeR1dine, is directly used in the next step without further puR1fication. [00147] Crude 4-{4-[3~Methyl-4-(tetrahydro-thiopyran-4-yl)-phenoxymethyl]- phenylj-pipeR1dine is dissolved in MeOH (8 mL) and treated with /-butyl acrylate (1.777 mmol, 228 mg, 0.26 mL) and D1EA (4.442 mmol, 574 mg, 0.77 mL). The resulting mixture is heated at 60 °C for 45 minutes. After concentration, the residue is partially puR1fied by silica gel chromatography (0 to 10% MeOH in DCM) to give crude 3-(4-{4-[3-MethyI-4-(tetrahydro-thiopyran-4-yl)-phenoxymethyl]-phenyl}-pipeR1din-l-yI)-propionic acid tert-butyl ester. [00148] To a solution of crude 3-(4-{4-[3-Methyl-4-(tetrahydro-thiopyran-4-yf)- phenoxymethyt]-phenyl}-pipeR1din-l-yl)-propionic acid tert-butyl ester in dry DCM (7 mL) is added tR1ethyl silane (5 eq., 4.442 mmol, 517 mg, 0.71 mL) followed by TFA (7 mL). The resulting mixture is stirred at room temperature for 1 hour. After concentration, the crude product is puR1fied by preparative RP LC-MS to give 3-(4-{4-f3-methyl-4-ftetrahydro-thiopvran-4-yl)-phenoxymethyl)-phenyl)-piper1din-l-yl)-propionic acid as a tan solid. 1H NMR (DMSO-d6, 400 MHz) 5 7.44-7.38 (m, 2H), 7.30-7.21 (m, 2H), 7.13-7.05 (m, 1H), 6.83-6.72 (m, 2H), 5.02 (s, 2H), 3.61-3.52 (m, 2H), 3.15-3.05 (m, 2H), 2.89-2.75 (mf 5H), 2.72-2.60 (m, 3H), 2.33-2.20 (m, 3H), 2.06-1.88 (m, 6H), 1.77-1,61 (m, IH); MS(ES+): (454.2, M+l)+. [00149] To a solution of 4-(4-hydroxy-phenyl)-pipeR1dine-l-carboxylic acid tert- butyl ester (1 eq) in anhydrous DMF is added NaH (1.1 eq) at room temperature. After 5 minutes, l-chloro^-chloromethyl-2-tR1fluoromethyl-benzene (1.1 eq) in DMF is added. The resulting mixture is stirred for 30 minutes. After aqueous work up, flash column chromatography (10% EtOAc/hexane) gave 4-[4-(4-Chloro-3-tR1fluoromethyl-benzyloxy)- phenyl]-pipeR1dine-l-carboxy!ic acid terNbutyl ester. [MS: (ES*) 490.3 (M+l)+). [00150J 4-[4-(4-Chloro-3-tR1fluoromethy]-benzyIoxy)-phenyl]-pipeR1dine-l- carboxylic acid tert-butyl ester (I eq) is dissolved in 10% TFA/DCM and stirred for 30 minutes. After concentration, the residue is re-dissolved in DCM and washed with saturated NaHC03 and bR1ne. The organic layer is dR1ed over Na2So4 and concentrated. The residue is then dissolved in MeOH and /-butyl acrylate (2 eq) is added. The resulting solution is heated at 90 °C in microwave for 10 minutes. After concentration, puR1fication by flash column chromatography (80% EtOAc/hexane) gave 3-{4-[4-(4-Chloro-3-tR1fluoromethyl-benzyloxy)-phenyl]-pipeR1din-l-yl}-propionic acid tert-butyl ester. [MS: (ES+) 498.2 (M+lfl. [00151] 3-{4-[4-(4-Chloro-3-tR1fluoromethyl-benzyloxy)-phenyI]-pipeR1din-l-yl}- propionic acid tert-butyl ester (1 eq) and Pd catalyst (0.05 eq) are treated with cyclohexyl zinc bromide in THF. The resulting mixture is heated at 100 °C in microwave for 25 minutes. It is then diluted with EtOAc and washed with 1 N HC1. After concentration, puR1fication by flash column chromatography (EtOAc) gave 3-{4-[4-(4-CycIohexyl-3-tR1fluoromethyl-benzyloxy)-phenyl]-pipeR1din-l-yl}-propionic acid tert-butyl ester. [MS: (ES+) 546.3 (M+l)*]. [00152] 3-{4-[4-(4-Cyclohexyl-3-tR1fluoromethyl-benzyloxy)-phenyl]-pipeR1din-l' yl}-propionic acid tert-butyl ester is dissolved in DCM and treated with TFA (50% v/v). After 2 h at room temperature, it is concentrated to give a residue which is puR1fied by RP LC-MS to give 3-{4-[4-(4-Cyclohexyl-3-tR1fluoromethyl-benzyioxy)-phenyl]-pipeR1din-l-y!}-propionic acid. 1HNMR (400 MHz, CD3OD) 5 7.83 (1H, s), 7.65 (1H, d), 7.55 (1H, d), 7.20 (4H, m), 5.45 (2H, s), 3.66 (2H, d), 3.44 (2H, m)t 3.20 (2H, m), 2.81 (2H, m), 2.68 (2H, m), 1.84 (9H, m), 1.36 (5H, m). MS (ES+): 490.3 (M+l)+. [00153] l-Bromo-2-ethy!-4-methoxy-benzene (1 eq), piperazine-1-carboxylic acid tert-butyl ester (1.5 eq), Pd(OAc)2 (0.03 eq), phosphine iigand (0.06 eq), sodium /-butoxide (1.7 eq) are mixed in toluene and the resulting mixture is heated at 120 °C in microwave for 20 minutes. It is then diluted with EtOAc/hexane and filtered through celite. Flash column chromatography (20% EtOAc/hexane) gave4-(2-Ethyl-4-methoxy-phenyI)-piperazine-l-carboxylic acid tert-butyl ester. MS: (ES+): 321.2 (M+l)+. [00154] 4-(2-Ethyl-4-methoxy-phenyl)-piperazine-l-carboxyIic acid tert-butyl ester is refluxed in 48% HBr for 2 hours. After concentration, the residue is dissolved in DCM and (Boc)20 (1.5 eq) and tR1ethylamine (4 eq) are added. The resulting mixture is stirred at room temperature for 30 minutes. After aqueous workup, flash column chromatography (30% EtOAc/hexane) gave 4-(2-Ethyl-4-hydroxy-phenyI)-piperazine-l-carboxylic acid tert-butyl ester. MS: (ES+): 307.2 (M+l)+. [00155] 3-{4-[4-(4-CycIohexyl-3-tR1fluoromethy!-benzyloxy)-2-ethyl-phenyI]- piperazin-l-yl}-propionic acid is synthesized similarly the above reaction: 'HNMR (400 MHz, CD3OD) S 7.75 (1H, s), 7.66 (1H, d), 7.55 (1H, d), 7.21 (1H, m), 6.93 (2H, m), 5.10 (2H, s), 3.30 (10H, m), 2.94 (2H, m), 2.75 (2H, m), 1.80 (5H, m), 1.40 (8H, m). MS (ES+): 519.3 (M+l)+. [00156} To a mixture of 4-phenyl-3-methyl-phenoI (1 eq), 4-(4-hydroxymethyl- pheny!)-pipeR1dine-l-carboxy!ic acid tert-butyl ester (1 eq) and PPh3 (1.5 eq) in dry THF (3 mL) is added l,r-(azodicarbonyI)-dipippeR1dine (1.5 eq) in THF (1 mL). The mixture is stirred at room temperature for 12 hours. After concentration, the residue is puR1fied by silica gel chromatography (10% EtOAc in hexanes) to give 4~[4-(4-phenyl-3-methyl- phenoxymethyl)-phenyl]-pipeR1dine-I-carboxylic acid tert-butyl ester. [00157] A solution of above 4-[4-(4-phenyl-3-methyl-phenoxymethyl)-phenyl]- pipeR1dine-1-carboxylic acid tert-butyl ester in DCMyTFA (1:2 v/v, 3 mL) is stirred for 40 minutes. After concentration, the residue obtained is dissolved in methanol (2 mL). DIEA (5 eq) and f-butyl acrylate (2 eq) is added to this solution. The reaction mixture is heated at 90°C for 30 minutes using microwave irradiation. After concentration, the residue is puR1fied by silica gel chromatography (40% EtOAc in hexanes) to give 3-{4-[4-(4-phenyl-3-methyl-phenoxymethyl)-phenyl]-pipeR1din-l-yl}-propionic acid tert-butyl ester. This mateR1al is dissolved in DCM/TFA (1:1 v/v, 3 mL), and the solution is stirred at room temperature for 40 minutes. After concentration, the crude product is puR1fied by preparative RP LC-MS to give 3»f4*f4-(4-phenyl-3-methyl-phenoxymcthyl)-phenyl--piperidin-l-yl)-prooionic acid: MS (ES+): 430.6 (M+l)+. [00158] By repeating the procedure descR1bed in the above examples, using appropR1ate starting mateR1als, the following compounds of Formula I are obtained as identified in Table 1. [00159] EDG-1 (S1P1) GTP [y-35S] binding assay: Membrane protein suspensions are prepared from CHO cell clones stably expressing a human EDG-1 N-terminal c-myc tag. Solutions of test compounds ranging from l0mM to 0.01 nM are prepared in DMSO/50mM HCI and then diluted into assay buffer (20mM HEPES, pH7.4, l00mM NaCl, l0mM MgC12, 0.1 % fat free BSA). Assay buffer containing 10mM GDP is mixed with wheat germ agglutinin-coated SPA-beads (Img/well) followed by the addition of human EDG-1 membrane protein suspension (10 ng/well) and test compound. The bead/membrane/compound assay components are then mixed for 10-15 minutes on a shaker at room temperature. GTP [y-35S] (200pM) and bead/membrane/compound assay mixture are added to individual wells of a 96 well Optiplate ™ (final volume 225 /well), sealed and incubated at room temperature for 110 to 120 minutes under constant shaking. After centR1fugation (2000rpm, 10 minutes) luminescence is measured with a Topcon ™ instrument. [00160] EC50 values are obtained by fitting the GTP [y-35S] binding curves (raw data) with the dose response curve-fitting tool of OR1GIN V. 6.1. Basal binding (no compound) and the highest stimulation of GTP [y- S] binding achieved by an agonist are used as the fitting range. Seven different concentrations are used to generate a concentration response curve (using two or three data points per concentration). [00161] EDG-3,-5,-6 and -8 GTP [y-35S] binding assays are carR1ed out in a comparable manner to the EDG-I GTP [[y-35S] binding assay using membranes from CHO, or in the case of EDG-8 RH7777 membranes, from cells stably expressing c-terminai c-myc tagged or untagged receptors. Concentrations of EDG receptor expressing membranes range between 13-19 jag per well. Compounds of the invention were tested according to the above assay and were observed to exhibit selectivity for the S1P-1 (EDG-1) receptor. For example: (i) 3-(4-f4-(4-cyclohexyl-3-methvl-Dhenoxymethyl)-phenyl']--piperidin-l-yl-propionic acid (example 1) has an EC5o of 0.22 nM in the above assay and is at least 1000 fold selective for S1P-1 compared to one or more of the other receptors including S1P-3, S1P-5, SlP-6 and SlP-8; and (ii)3-[4-r4-r2-Methyl-biphenyl-4-yloxymethyl)-phenyl-piperidin-1-yl}-propionic acid (Example 8) has an EC50 of 2nM, >10µM, 2µM, >10µM and 370nM for S1P-1, S1P-2, S1P-3, S1P-4 and S1P-5, respectively. B. In vitro: FLIPR calcium flux assay [00162] Compounds of the invention are tested for agonist activity on EDG-1, EDG-3, EDG-5, and EDG-6 with a FLIPR calcium flux assay. BR1efly, CHO cells expressing an EDG receptor are maintained in F-12K medium (ATCC), containing 5% FBS, with 500ug/ml of G418. PR1or to the assay, the cells are plated in 384 black clear bottom plates at the density of 10,000 cells/well/25nl in the medium of F-12K containing 1% FBS. The second day, the cells are washed three times (25 µl/each) with washing buffer. About 25 |d of dye are added to each well and incubated for 1 hour at 37°C and 5% CO2. The cells are then washed four times with washing buffer (25 µl/each). The calcium flux is assayed after adding 25 µl of SEQ2871 solution to each well of cells. The same assay is performed with cells expressing each of the different EDG receptors. Titration in the FLIPR calcium flux assay is recorded over a 3-minute interval, and quantitated as maximal peak height percentage response relative to EDG-1 activation. C. In vivo: Screening Assays for measurement of blood lymphocyte depletion and assessment of heart effect [00163] Measurement of circulating lymphocytes: Compounds are dissolved in DMSO and diluted to obtain a final concentration of 4% DMSO (v/v, final concentration) and then further diluted in a constant volume of Tween80 25%/H20, v/v. Tween80 25%/H20 (200 µl), 4% DMSO, and FTY720 (l0µg) are included as negative and positive controls, respectively. Mice (C57bl/6 male, 6-10 week-old) are administered 250-300 µL of compound solution orally by gavages under short isoflurane anesthesia. [00164] Blood is collected from the retro-orbital sinus 6 and 24 hours after drug administration under short isoflurane anesthesia. Whole blood samples are subjected to hematology analysis. PeR1pheral lymphocyte counts are determined using an automated analyzer. Subpopulations of peR1pheral blood lymphocytes are stained by fluorochrome-conjugated specific antibodies and analyzed using a fluorescent activating cell sorter (Facscalibur). Two mice are used to assess the lymphocyte depletion activity of each compound screened. The result is an ED50, which is defined as the effective dose required displaying 50 % of blood lymphocyte depletion. Compounds of the invention were tested according to the above assay and were preferably found to exhibit an ED50 of less than lmg/kg, more preferably an ED50 of less than 0.5 mg/kg. For example: (i) 3-f4-f4-f4-cvclohexvl-3"methyl-phenoxymethyl-phenyl--piperidin-l-yl-propionic acid (example I) exhibits an ED50 of 0.1 mg/kg; and (ii) 3-f4-[4-(2-methyl-biphenyl-4-vloxymethylV phenvll-piperidin-l-yl)-propionic acid (Example 8) exhibits and ED50 of 0.2mg/kg and G.8mg/kg at 6 and 48 hours, respectively. [00165] Assessment of Heart Effect: The effects of compounds on cardiac function are monitored using the AnonyMOUSE ECG screening system. Electrocardiograms are recorded in conscious mice (C57bl/6 male, 6-10 week-old) before and after compound administration. ECG signals are then processed and analyzed using the e-MOUSE software. 90 µg of compound further diluted in 200µ1 water, 15% DMSO are injected IP. Four mice are used to assess the heart effect of each compound. D: In vivo: Anti-aneiogenic Activity [00166] Porous chambers containing (i) sphingosine-1-phosphate (5 ^M/chamber) or (ii) human VEGF (1 fig/chamber) in 0.5 ml of 0.8% w/v agar (containing hepaR1n, 20 U/ml) are implanted subcutaneously in the flank of mice. SI P or VEGF induces the growth of vasculaR1zed tissue around the chamber. This response is dose-dependent and can be quantified by measuR1ng the weight and blood content of the tissue. Mice are treated once a day orally or intravenously with a compound of formula I starting 4-6 hours before implantation of the chambers and continuing for 4 days. The animals are sacR1ficed for measurement of the vasculaR1zed tissues 24 hours after the last dose. The weight and blood content of the vasculaR1zed tissues around the chamber is determined. Animals treated with a compound of formula 1 show reduced weight and/or blood content of the vasculaR1zed tissues compared to animals treated with vehicle alone. Compounds of Formula I are anti-angiogenic when administered at a dose of about 0.3 to about 3mg/kg. E: In vitro: Antitumor Activity [00167] A mouse breast cancer cell line oR1ginally isolated from mammary carcinomas is used, e.g. JygMC(A). The cell number is adjusted to 5xl05 for plating in fresh medium before the procedure. Cells are incubated with fresh medium containing 2.5mM of thymidine without FCS for 12 hours and then washed twice with PBS, followed by addition of fresh medium with 10% FCS and additionally incubated for another 12 hours. Thereafter the cells are incubated with fresh medium containing 2.5mM of thymidine without FCS for 12 hours. To release the cells from the block, the cells are washed twice with PBS and replated in fresh medium with 10% FCS. After synchronization, the cells are incubated with or without vaR1ous concentrations of a compound of formula I for 3, 6, 9, 12, 18 or 24 hours. The cells are harvested after treatment with 0.2% EDTA, fixed with ice-cold 70% ethanol solution, hydrolyzed with 250µg/ml of RNaseA (type 1-A: Sigma Chem. Co.) at 37°C for 30 minutes and stained with propidium iodide at l10mg/ml for 20 minutes. After the incubation peR1od, the number of cells is determined both by counting cells in a Coulter counter and by the SRB coloR1metR1c assay. Under these conditions compounds of formula I inhibit the proliferation of the tumor cells at concentrations ranging from 10*12 to I0"6 M. [00168] It is understood that the examples and embodiments descR1bed herein are for illustrative purposes only and that vaR1ous modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spiR1t and understanding of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes. WE CLAIM in which: n is chosen from 0, 1 and 2; m is chosen from 1, 2 and 3; R1 is chosen from C6-10aryl and C5-10heteroaryl; wherein any aryl or heteroaryl of R1 is optionally substituted by a radical chosen from C6-10arylC0-4alkyl, C5-6heteroarylC0-4alkyl, C3-8cycloalkylC0-4alkyl, C3-6heterocycloalkylC^alkyl orC1-10alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R1 can be optionally substituted by 1 to 5 radicals chosen from halo, C1-10alkyl, C1-10afkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-10alkoxy; and any alkyl group of R| can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, -S(o)r~, -NR7- and -O-; wherein R? is chosen from hydrogen and C1-6alkyl; R2, R1, R4 and R5 are independently chosen from hydrogen, halo, hydroxy, C1-. 10alkyI,1-10aIkoxy, halo-substituted-C1-10alkyl and halo-substituted-Ct.joalkoxy; A is chosen from -X,C(o)OR7, -X(o)P(o)(oR7)2, -X,P(o)(OR7)2, - X1P(o)OR7, -X,S(o)2OR7, -X1P(o)(R7)OR7 and ltf-tetrazol-5-yl; wherein X, is chosen from a bond, C1-3alkylene and C2_3alkenylene and R7 is chosen from hydrogen and C1-4alkyl; B is CR8R9, wherein R8 and R9 are independently chosen from hydrogen, hydroxy,C1-10alkyl, C1-10alkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-toalkoxy; E is chosen from CR8 or N; wherein R8is chosen from hydrogen, hydroxy, C1-15 alkyl, C1-10alkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-calkoxy; or B is CR9 and E is carbon and B and E are connected via a double bond; X is a bond or is chosen from -X,OX2- -X|NR7X2- -X,C(o)NR7X2-, - X,NR7C(o)X2- -X,S(o)X2- -X,S(o)2X2-, -X1sX, C4-6heteroarylene and -XiON=C(R7)X2-; wherein Xj and X2 are independently chosen from a bond, C|.3alkylene and C2.-3alkenylene; R7 is chosen from hydrogen and C1-6alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and Chalkyl Y is chosen from C1-10aryl and Cs-ioheteroaryl, wherein any aryl or heteroaryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydoxy, nitro, C1_ 10alkyl,C1-10alkoxy, halo-substituted C1-10alkyl and halo-substituted C1-10alkoxy; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof. 2. The compound of claim 1 in which R1 is chosen from phenyl, naphthyl and thiophenyf optionally substituted by C6-10arylC0-4a!kyl, Cs^heteroarylC0-4alkyl, C3-8cycloalkylC0=4alkyl, C3-8heterocycloalkylC0-4alkyl or C1-10oalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R1 can be optionally substituted by 1 to 5 radicals chosen from halo, C1-10alkyl,C1-10alkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-10alkoxy; and any alkyl group of R1 can optionally have a methylene replaced by an atom or group chosen from -S-, -S(o}-, -S(o)2-, -NR7- and -O-; wherein R7 is hydrogen or Chalky!. 3. The compound of claim 1 in which A is chosen from -X1C(o)OR7 and 1//-tetrazol-5-yl; wherein Xi is chosen from a bond, C1-3alkylene and C2-3aIkenylene and R7 is chosen from hydrogen and C1-6alkyl. 4. The compound of claim I in which X is chosen from: wherein the left and right asterisks of X indicate the point of attachment between R1 and Y of Formula 1, respectively; R7 is chosen from hydrogen and C1-6alkyl; v and w are independently 0, 1, 2 or 3. 5. The compound of claim 1 in which Y is chosen from: wherein R7 is hydrogen or C1-6alkyl; and the left and right asterisks of Y indicate the point of attachment between X and E of Formula I, respectively. 6. The compound of claim 2 in which R1 is chosen from: wherein the asterisk is the point of attachment of R1 with X; R10 is C6-10arylCo-4alkyl, Cs-eheteroarylCo^alkyl, Ca-scycloalkylC0-4alkyl, Cs-sheterocycloalkylC0-4alkyl or C0-4calkyl; wherein any aryJ, heteroaryl, cycloalkyl or heterocycloalkyl group of Rio can be optionally substituted by 1 to 3 radicals chosen from halo, CMOalkyl, C1-10alkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-10atkoxy; and any alkyl group of Rio can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, -§{0)2-, -NR7- and -O-; wherein R7 is hydrogen or Chalky!; and R| 1 is selected from halo, Ci-jcalkyl,C1-10alkoxy, halo-substituted-C1-10alkyI and halo-substituted-C1-10alkoxy. 7. The compound of claim 2 selected from: 3-{4-[6-(4-CycIohexyI-3- trifluoromethyl-benzyloxy)-pyridin-3-yl]-piperazin-l-yl}-propionic acid; 3-{4-[6-(4- Cyc]ohexyl-3-trifluoromethyl-phenoxymethyl)-pyridin-3-yl]-piperazin-l-yl}-propionic acid; 3-{4-[6-(4-Cyclohexyl-3-tnfluoromethyl-benzyloxy)-pyrida2in-3-yI]-piperazin-l-yl}-propionic acid; 3-{4-[2-(4-CyclohexyI-3-trifluoromethyi-benzyloxy)-pyrimidin-5-yI]-piperazin-l-yl}-propionic acid; 3-{4-Hydroxy-4-[2-(2-trifluoromethyl-biphenyl-4-yI)-benzo[b]thiophen-5-yl]-piperidin-l-yl}-propionic acid; 3-{4-[2-(2-Trif1uoromethyl-biphenyI-4-yl)-benzo[b]thiophen-5-y!]-3,6-dihydro-2H-pyridin-l-yI}-propionic acid; 3-(3-{4-[3-(2-Trifluoromethyl-biphcnyl-4-yI)-[l,2,4]oxadiazol-5-yl]-phenyl}-pyrroIidin-l-yI)-propionic acid; 3-(3-{3-[5-(4-CycIohcxyl-3-trifluoromethyI-phenyI)-[l,3,4]oxadiazol-2-yl]-phenyl}-pyrrolidin-l-yl)-propionic acid; 3-(3-{3-[5-(2-Trifluoromethyl-biphenyl-4-yI)-[U3,4]oxadiazol-2-yl]-phenyl}-pyrrolidin-1-yI)-propionic acid; 3-(3-{4-[3-(4-Cyclohexyl-3-trifluoromethyl-phenylHl,2,4]oxadiazol-5-yl]-phenyl}-pyrrolidin-1-yl)-propionicacid; 3-(4-{4-[5-(4-CyclohexyI-3-trifluoroniethyl-phenyl)-[l,314]oxadiazoU2-yI]-phenyI}-piperidin-l-y!)-propionicacid; 3-(3-{4-[5-(4-CycIohcxyl-3-trifIuoromethyl-phcnyI)-[l,3>4]oxadiazoI-2-yl]-phenyI}-pyrrolidin-l-yI)-propionicacid; 3-(3-{4-[5-(2-Trifluoromethyl-bipheny!-4-yl)-[l,3,4]oxadiazol-2-yI]-phenyl}-pyrro!idin-l-yl)-propionicacid; 3-(4-{4-[5-(2-Trifluoromethyl-biphenyl-yl-HI-oxadiazol-ylj-phenyl--piperidin-l-yl^propionic acid; 3-(3-{4-[5-(4-Cyclohexyl-3-trinuoromethyl-phenyl)-[l,3s4]oxadiazol-2-y]]-phenyl}-azetidin-l-y!)-propionicacid; 3-(3-{4-[5-(2-Trifluoromethyl-biphenyI-4-yl)-[l^^Joxadiazol^-y^-phenylJ-azetidin-l-yO-propionicacid; 3-(4-{4-[5-(3-Trifluoromethyl-phenyI)-[l,3,4]oxadiazol-2-yI]-phenyl}-piperidin-l-y])-propionicacid; 3-{4-[6-(2-TrifluoromethyI-biphenyl-4-yloxymethyI)-pyridin-3-yl]-piperazin-l-yl}-propionicacid; and 3-{4-[4-(2-Trifluoromethyl-biphenyl-4-ylsuIfanylmethyI)-phenyl]-piperidin-l-yl}-propionic acid. in which: E is selected from N and CH; m and n are independently selected from 0 and 1; v and w are independently selected from 0 and 1; Rio is selected from cyclohexyl, piperidinyl, tetrahydro-thiopyran-4-yl, phenyl, phenoxy and phenylsulfanyl; wherein any cyclohexyl, piperidinyl, tetrahydro-thiopyran-4-yl, phenyl, phenoxy and phenylsulfanyl of R10 can be optionally substituted by 1 to 3 radicals independently selected from methyl and isopropyl; Ri i is selected from methyl, trifluoromethyl and ethyl; and R12 is selected from hydrogen, ethyl and methoxy. 9. The compound of claim 8 selected from: 3-{4-[4-(4-Cyclohexyi-3-methyI-phenoxymethyl)-phenyl]-piperidin-l-yl}-propionicacid; 3-{4-[4-(4-Piperidin-I-yl-3-trifluoromethy]-phenoxymethyl)-phenyl]-piperidin-l-yl}-propionicacid; 3-(4-{4-[3-Methyl-4-(tetrahydro-thiopyran-4-yI)-phenoxymethyl]-pheny!}-piperidin-1 -yl)-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-phenyI]-piperidin-l-yl}-propionicacid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl"benzyloxy)-2-ethyl-phenyl]-piperazin-l-yl}-propionic acid; 3-{4-[4-(2-Methyi-biphenyl-4-yloxymethyl)-phenyl]-piperidin-l-yl}-propionic acid; 3-{4-[4-(2-TrifluoromethyI-biphenyl-4"yloxymethyl)-phenyI]-piperidin-l -yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-phenoxymethyl)-phenyl]-piperidin-I-yl}-propionicacid; 3-{4-[4-(3'-MethyI-2-trifluoromethyI-biphenyl-4-yloxymethyl)-phenyl]-piperidin-l-yl}-propionic acid; 3-{3-[4-(4-Cyclohexyl-3-trifluoromethyl-phenoxymethyl)-phenyl]-pyrrolidin-l-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-ethyl-phenoxymethyl)-phenyl]-piperidin-l-yl}-propionicacid; 3-{3-[4-(2-Triiluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-pyrrolidin-1 -yl}-propionic acid; 3-(4-{4-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-trifluoromethyl-phenoxymethyI]-phenyl}-piperidin-l-yl}-propnic acid; 3-{3-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-phenyl]-azetidin-l-yl}-propionic acid; 3-{3-[4-(2-Trifluoromethyl-biphenyI-4-yloxymethyI)-phenyl]-azetidin-l-yi}-propnicacid; 3-{4-[2-Ethyl-4-(2-trifluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yI}-propionic acid; 3-{3-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyIoxy)-phenyl]-pyrrolidin-l-y!}-propionicacid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl- benzyIoxy)-2-ethyl-phenyl]-piperidin-l-yl}-propionic acid; 3-{4-[4-(4'-Methyl-2-trifluoromethyl-biphenyl-4-yloxymethyl)-phenyI]-piperidin-l-yl}-propionic acid; 3-{4-[4-(4-Phenoxy-3-trifluoromethyl-phenoxymethyI)-phenyl]-piperidin-l-yl}-propionic acid; 3-{4-[4-(4-CycIohexyl-3-trifluoromethyl-phenoxymethyI)-2-methoxy-phenyl]-piperazin-l-yI}-propionic acid; 3-{4-[4-(2-Tnfluoromethyl-biphenyI-4-ylmethoxy)-phenyl]-piperidin-l-yl}-propionic acid; 3-{3-[4-(2-Trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]«pyrrolidin-l-yl}-propionic acid; 3-{3-[4-(2-TrifluoromethyI-biphcnyl-4-ylmethoxy)-phenyl]«a2etidin-l-yl}-propionic acid; 3-{4-[4-(4-Isobutyl-3-trifluoromethyl-benzyloxy)-phenyl]-piperidin-l-y!}-propionic acid; 3-{4-[4-(4-PhenylsulfanyI-3-trifluoromethyl-phenoxymethyI)-phenyl]-piperidin-1 -yI}-propionic acid; 1 -(I H-TetrazoI-5-yImethyl)-4-[4-(2-trifluoromethyI-biphenyI-4-ylmethoxy)-phenyl]-piperidine; l-[2-(lH-Tetrazol-5-yi)-ethyl]-4-[4-(2-trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-piperidine; 3-{4-[4-(2>4'-DimethyI-biphenyl-4-yloxymethyI)-phenyl]-piperidin-l-yl}-propionic acid; 3-{4-[4-(2,4'-Dimethyl-biphenyl-4-ylmethoxy)-phcnyl]-pipcridin-l-yl}-propionic acid; 3-{4-[4-(2-Ethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-l-yl}-propionic acid; 3-{4-[4-(2-Ethyl-3,-methyl-biphenyl-4-yIoxymethyI)-phenyI]-piperidin-l-yI}-propionicacid; (2-{4-[4-(2-Trifluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yI}-ethyl)-phosphonic acid; 2-{4-[4-(2-Trifluoromethyl-biphenyI-4-yloxymethyl)-phenyI]-piperidin-l-yI}-ethanesuIfonicacid; and Phosphoric acid mono-(2-{4-[4-(2-trifluoromethyl-biphenyI-4-yloxymethyI)-phenyl]-pipcridin-1-yl}-ethyl) ester. 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient. 11. A method for treating a disease in an animal in which alteration of EDG/S1P receptor mediated signal transduction can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1. 12. A method for preventing or treating disorders or diseases mediated by lymphocytes, for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, for inhibiting or controlling deregulated angiogenesis, or for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject comprising administering to the subject in need thereof an effective amount of a compound of claims!, or a pharmaceutically acceptable salt thereof. 13. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which alteration of EDG/S1P receptor mediated signal transduction contributes to the pathology and/or symptomology of the disease, 14. A process for preparing a compound of Formula I: in which: n is chosen from 0, 1 and 2; m is chosen from 1, 2 and 3; R1 is chosen from C4-10aryl and C5-10heteroaryl; wherein any aryl or heteroaryl of Ri is optionally substituted by a radical chosen from C6-10arylC0-4alkyl, C5-6heteroarylCo-4alkyl, C3.-8cycloalkylC0-4alkyl, C3-8heterocycloalkylC0-4alkyl orC1-10oalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of Ri can be optionally substituted by I to 5 radicals chosen from halo, C1-10alkyl, C1-10alkoxy, halo-substituted-C1-10alkyl and halo-substituted-C1-10alkoxy; and any alkyl group of R1 can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, -S(o)r-, -NR7- and -O-; wherein R7 is chosen from hydrogen and Chalky I; R2, R3, R4 and R5 are independently chosen from hydrogen, halo, hydroxy, C1-10caikyl, Cuioalkoxy, halo-substituted-C1-10alkyI and halo-substituted-C1-10alkoxy; A is chosen from -X,C(o)OR7, -X,OP(o)(OR7)2, -X, P(o)(OR7)2, - XlP(o)OR7, -XiS(o)2OR7) -X|P(o)(R7)OR7 and ltf-tetrazoI-5-yl; wherein X, is chosen from a bond, Ctoalkylene and C2-3alkenylene and R7 is chosen from hydrogen and C|1-6alkyl; B is CR8R.9; wherein R8 and R9 are independently chosen from hydrogen, hydroxy, C1-10alkyl, CMoalkoxy, halo-substituted-Cnoalkyl and halo-substituted-C1-10alkoxy; E is chosen from CR8or N; wherein R8 is chosen from hydrogen, hydroxy, Cncalkyl, C1-10alkoxy, haio-substituted-C1-10alkyl and halo-substituted-alkoxy; or B is CR9 and E is carbon and B and E are connected via a double bond; X is a bond or is chosen from -X,OX2- -X,NR7X2- -X,C(0)NR7X2- - X,NR7C(o)X2-, -X,S(o)X2- -X|S(o)2X2- -X.SX, C4.6heteroaryIene and -X1ON=C(R?)X2-; wherein X1and X2 are independently chosen from a bond, C1-3alkylene and C2oaIkenylene; R7 is chosen from hydrogen and C1-6alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and Chalkyl; Y is chosen from C6-10aryl and C1-10heteroaryl, wherein any aryl or heteroaryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydoxy, nitro, C1-. 10alkyl,C1-10alkoxy, halo-substituted C1-10alkyl and halo-substituted C1-10alkoxy; which process comprises: (a) reacting a compound of formula 2: with either /-butyl acrylate, acylonitrile/NaN3 or bromoacetonitrile/NaN3; wherein B, E, Y, X, R1 R2, R3, R4 and R5 are as described above; and (b) optionally converting a compound of the invention into a pharmaceutical ly acceptable salt; (c) optionally converting a salt form of a compound of the invention to a non-salt form; (d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutical ly acceptable N-oxide; (e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form; (f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; (g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and (h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form. |
|---|
| Patent Number | 253897 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 3059/CHENP/2006 | ||||||||||||||||||||||||||||||
| PG Journal Number | 36/2012 | ||||||||||||||||||||||||||||||
| Publication Date | 07-Sep-2012 | ||||||||||||||||||||||||||||||
| Grant Date | 31-Aug-2012 | ||||||||||||||||||||||||||||||
| Date of Filing | 22-Aug-2006 | ||||||||||||||||||||||||||||||
| Name of Patentee | IRM LLC | ||||||||||||||||||||||||||||||
| Applicant Address | Hurst Holme, 12 Trott Road, Hamilton HM 11, | ||||||||||||||||||||||||||||||
Inventors:
|
|||||||||||||||||||||||||||||||
| PCT International Classification Number | A61K 31/497 | ||||||||||||||||||||||||||||||
| PCT International Application Number | PCT/US2005/006311 | ||||||||||||||||||||||||||||||
| PCT International Filing date | 2005-02-24 | ||||||||||||||||||||||||||||||
PCT Conventions:
|
|||||||||||||||||||||||||||||||